KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs. The company is primarily focused on developing treatments for hereditary angioedema (HAE), a rare genetic condition characterized by episodes of painful swelling. KalVista does not currently sell any products but is advancing its lead candidate, sebetralstat, through regulatory approval processes and conducting preclinical research on additional therapeutic programs.
-
Sebetralstat - A novel, small molecule plasma kallikrein inhibitor being developed as the first oral, on-demand therapy for hereditary angioedema (HAE). The drug has completed the phase 3 KONFIDENT trial and is under regulatory review following the submission of a New Drug Application (NDA) in June 2024.
-
Factor XIIa Inhibitor Program - A preclinical program focused on developing oral Factor XIIa inhibitors for next-generation HAE therapeutics. This program also explores potential applications in other diseases with high unmet medical needs.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Benjamin L. Palleiko Executive | Chief Executive Officer | None | Benjamin L. Palleiko is the CEO of KalVista Pharmaceuticals. He has also held roles as Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer. No external roles are listed. | View Report → |
Brian Piekos Executive | Chief Financial Officer | None | Brian Piekos joined KalVista as CFO in September 2024. He previously held CFO roles at Elicio Therapeutics and Gemini Therapeutics and has extensive experience in corporate finance and biopharma leadership. | |
Christopher M. Yea Executive | Chief Development Officer | None | Christopher M. Yea has been with KalVista since November 2015 as Chief Development Officer. He has extensive experience in drug development, previously serving as COO at Vantia, Ltd.. | |
Jeb Ledell Executive | Chief Operating Officer | None | Jeb Ledell became COO of KalVista in December 2024. He has over 20 years of experience in operational leadership, previously serving as COO at AVEO Pharmaceuticals and Enzyvant Therapeutics. | |
Paul K. Audhya Executive | Chief Medical Officer | None | Paul K. Audhya joined KalVista in May 2021 as CMO. He has held senior roles at Arena Pharmaceuticals, Vertex Pharmaceuticals, and Hospira, focusing on advancing KalVista's therapeutic programs. | |
Brian J. G. Pereira Board | Chairman of the Board | President & CEO of Visterra, Inc.; Board Member at ProKidney Corp., Visterra, Inc., and Africa Healthcare Network Ltd.; Director at America India Foundation; Adjunct Professor at Tufts University School of Medicine. | Brian J. G. Pereira has been Chairman of KalVista's Board since October 2022. He has extensive experience in biopharma leadership and academic roles, with a focus on rare diseases and healthcare innovation. | |
Edward W. Unkart Board | Director | None | Edward W. Unkart has been a director at KalVista since December 2014. He is a CPA with extensive experience in finance and accounting, having served on the boards of XTENT and VNUS Medical Technologies. | |
Laurence Reid Board | Director | Chair of the Board at Broken String Biosciences; Board Member at Garuda Therapeutics; Board Advisor to Life Science Cares and Mount Auburn Hospital. | Laurence Reid joined KalVista's Board in November 2024. He has over 30 years of experience in biopharma leadership, previously serving as CEO of Decibel Therapeutics and Warp Drive Bio. | |
Nancy Stuart Board | Director | Board Member at The Greater Boston YMCA. | Nancy Stuart has been a director at KalVista since March 2021. She has extensive experience in strategic planning and business operations, previously serving as COO at Concert Pharmaceuticals. | |
Patrick Treanor Board | Director | Board Member at XORTX Therapeutics. | Patrick Treanor joined KalVista's Board in May 2022. He has held senior commercial roles at Pathalys Pharma, Relypsa, and Insulet Corporation, focusing on operational leadership and commercialization. | |
William Fairey Board | Director | Board Member at Ascendis Pharma, Aileron Therapeutics, Mirum Pharmaceuticals, and Respira Therapeutics. | William Fairey joined KalVista's Board in April 2024. He has held senior commercial roles at MyoKardia, ChemoCentryx, and Actelion Pharmaceuticals, focusing on rare and specialty diseases. |
Research analysts covering KalVista Pharmaceuticals.
Recent press releases and 8-K filings for KALV.
- KalVista Pharmaceuticals presented new data from its KONFIDENT and KONFIDENT-S studies for EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), at the 20th German Allergy Congress.
- The studies demonstrated EKTERLY's ability to rapidly halt the progression of HAE attacks in a median of 20 minutes and deliver symptom relief in a median of 1.6 hours among European participants.
- A patient survey highlighted that 53% of respondents experienced injection-site reactions with current injectable therapies, contributing to a mean treatment delay of 3.9 hours.
- With EKTERLY now approved in the European Union, KalVista plans to launch in Germany this quarter (Q4 2025) followed by additional European launches in 2026 and beyond.
- KalVista Pharmaceuticals has appointed Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025, to support the global launch of EKTERLY, the first oral on-demand treatment for hereditary angioedema (HAE).
- Arif brings over 25 years of biopharmaceutical operations experience, and Aspesi has over 25 years of human resources leadership in biopharmaceutical and healthcare industries.
- Both executives will receive inducement stock options to purchase 100,000 shares each of KalVista common stock, vesting over four years, to align their incentives with the company’s long-term growth.
- The company faces financial challenges, including negative EBITDA and cash burn, but maintains strong liquidity and has strategic growth opportunities, with analyst price targets ranging from $20 to $40.
- KalVista Pharmaceuticals priced an upsized offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031, an increase from the previously announced $110.0 million.
- The notes will bear interest at 3.250% per year, payable semi-annually on April 1 and October 1, commencing October 1, 2026, and will mature on October 1, 2031.
- The initial conversion rate is 59.4919 shares of common stock per $1,000 principal amount of notes, equivalent to an initial conversion price of approximately $16.81 per share, representing an approximate 30.0% premium based on the September 24, 2025, closing price of $12.93 per share.
- KalVista expects net proceeds of approximately $120.8 million (or up to $139.0 million if the initial purchasers' option to purchase additional notes is fully exercised). These proceeds are intended for working capital, general corporate purposes, including the commercialization of EKTERLY, and potential investments or acquisitions.
- KalVista Pharmaceuticals announced plans to issue $110 million in convertible senior notes due in 2031 via a private placement.
- The proceeds will primarily support working capital and the commercialization of EKTERLY, their FDA-approved drug for hereditary angioedema (HAE), which also recently received European Commission and Swissmedic approval.
- Following the announcement, KalVista's shares dropped 10.3% post-market, closing at $11.60.
- All ten analysts covering the stock maintain a bullish outlook, with a median price target of $30.
- KalVista Pharmaceuticals reported $1.4 million in net revenue for the launch period of EKTERLY in Q1 2026, with total operating expenses of $60.4 million, including $45 million in SG&A primarily due to the EKTERLY launch.
- The company held approximately $191 million in cash and investments as of July 31, 2025, projecting this, along with forecasted EKTERLY revenue, to fund operations into 2027.
- EKTERLY received FDA approval on July 7, 2025, and its U.S. launch immediately followed, showing strong early uptake with 460 patient start forms and 253 unique prescribers by August 29.
- Global regulatory progress for EKTERLY includes a positive CHMP opinion in Europe, UK marketing authorization (with commercial launch anticipated in the first half of 2026), and expected approval in Japan by year-end 2025 for an early 2026 launch.
- KalVista Pharmaceuticals announced the FDA approval of ECTERLEET on July 7th, 2025, as the first and only oral on-demand therapy for acute hereditary angioedema (HAE) attacks, and immediately initiated its U.S. launch.
- For Q1 2026, ending July 31, 2025, the company reported $1.4 million in net revenue from initial ECTERLEET sales, primarily from stocking orders.
- Early U.S. launch metrics for ECTERLEET, through August 29, include 460 patient start forms and 253 unique prescribers activated.
- As of July 31, 2025, KalVista held approximately $191 million in cash and investments, which, combined with forecasted ECTERLEET revenue, is expected to fund operations into 2027.
- Internationally, ECTERLEET received a positive CHMP opinion in Europe, UK marketing authorization with anticipated commercial launch in H1 2026, and expected approval in Japan by year-end with launch in early 2026.
- KalVista Pharmaceuticals announced FDA approval of ECTERLEET on July 7th as the first and only oral on-demand therapy for acute hereditary angioedema (HAE) attacks, initiating its U.S. launch immediately.
- For the first fiscal quarter ending July 31, 2025, the company reported $1.4 million in net revenue from initial ECTERLEET sales, primarily from stocking orders. Early U.S. launch metrics through August 29th include 460 patient start forms received and 253 unique prescribers activated.
- As of July 31, 2025, KalVista had $191 million in cash and investments, which is expected to fund operations into 2027.
- The company is also progressing with international regulatory efforts for ECTERLEET, including a positive CHMP opinion in Europe, MHRA marketing authorization in the UK, and anticipated approval in Japan by the end of 2025.
- KalVista Pharmaceuticals announced the FDA approval of ECTERLEET on July 7th and immediately initiated its U.S. launch as the first and only oral on-demand therapy for acute hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.
- For the three-month period ending July 31st, 2025, the company reported $1.4 million in net revenue from initial ECTERLEET sales.
- Early U.S. launch metrics for ECTERLEET include 460 patient start forms received and 253 unique prescribers activated in the eight-week period ending August 29.
- As of July 31st, 2025, KalVista had approximately $191 million in cash and investments, which, combined with forecasted ECTERLEET revenue, is expected to fund operations into 2027.
- Internationally, ECTERLEET received a positive CHMP opinion in Europe in July, with a final European Commission decision expected in October, and UK marketing authorization, anticipating launches in Europe over the next 12 to 18 months and the UK in the first half of 2026.
- KalVista Pharmaceuticals reported $1.4 million in net product revenue for the fiscal quarter ended July 31, 2025, primarily from US sales of EKTERLY, and a net loss of $60.1 million for the same period.
- The company initiated the US commercial launch of EKTERLY (sebetralstat) on July 7, 2025, following FDA approval, and received 460 patient start forms through August 29, 2025.
- EKTERLY also received marketing authorization in the United Kingdom in July 2025, and the European Medicines Agency (EMA) adopted a positive opinion recommending approval of sebetralstat, with a final decision expected in October 2025.
- As of July 31, 2025, KalVista had $191.5 million in cash, cash equivalents, and marketable securities, providing a runway into 2027.
- KalVista Pharmaceuticals announced the maintenance of orphan designation for sebetralstat in the European Union (EU).
- This designation provides 10 years of market exclusivity in the EU if sebetralstat is approved.
- Sebetralstat, an oral plasma kallikrein inhibitor, has received a positive CHMP opinion for the treatment of acute attacks of hereditary angioedema (HAE), with the European Commission's final decision expected by early October.
- Sebetralstat is already approved in the United States and United Kingdom under the brand name EKTERLY® for the treatment of HAE attacks.